State Street Corp Purchases 512,682 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

State Street Corp raised its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 52.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 1,496,739 shares of the company’s stock after buying an additional 512,682 shares during the quarter. State Street Corp’s holdings in Aquestive Therapeutics were worth $7,454,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Verition Fund Management LLC acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $995,000. Blue Owl Capital Holdings LP increased its stake in Aquestive Therapeutics by 30.3% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after buying an additional 265,000 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Aquestive Therapeutics in the 2nd quarter valued at $594,000. Chartwell Investment Partners LLC bought a new stake in Aquestive Therapeutics during the 3rd quarter worth about $535,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Aquestive Therapeutics by 252.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after buying an additional 13,481 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Down 3.8 %

Shares of NASDAQ AQST opened at $3.52 on Friday. Aquestive Therapeutics, Inc. has a twelve month low of $1.95 and a twelve month high of $6.23. The company has a market cap of $320.95 million, a PE ratio of -7.82 and a beta of 2.62. The business’s 50 day moving average price is $4.61 and its two-hundred day moving average price is $4.09.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period last year, the firm earned ($0.03) earnings per share. As a group, research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AQST has been the topic of a number of recent research reports. Leerink Partners lifted their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Finally, JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $11.00.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.